This Author published in this journals
All Journal MEDICINUS
Anindya Oktafiani
Bagian Ilmu Kesehatan Kulit dan Kelamin, Fakultas Kedokteran, Universitas Sebelas Maret Surakarta/RSUD Dr. Moewardi, Surakarta

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Profil Pemphigus Vulgaris di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta Periode Januari 2014-Desember 2019 Eka Devinta Novi Diana; Wibisono Nugraha; Alfina Rahma; Frieda; Anindya Oktafiani; Rieska Widyaswari; Muhammad Eko Irawanto
MEDICINUS Vol 34 No 3 (2021): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (111.003 KB) | DOI: 10.56951/medicinus.v34i3.79

Abstract

Background: Pemphigus vulgaris is life-threatening autoimmune bullous disease caused by acantholysis of keratinocytes and disruption of adhesion function of desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3). The clinical manifestation of pemphigus vulgaris is flaccid bullae that affect all parts of the body with mucosal involvement. This study aimed to evaluate profile of pemphigus vulgaris cases among hospitalized patients in Dr.Moewardi General Hospital Surakarta Januari 2014-December 2019. Methods: This descriptive retrospective study was conducted using medical record data of pemphigus vulgaris patients hospitalized at Dr.Moewardi General Hospital Surakarta between January 2014 and December 2019. Results: Total pemphigus vulgaris cases in 6 years is 25 cases, with most affected age range was 51-60 years (36%), and dominated by female (80%). Mucocutaneous involvement was found in 60% cases and the most common comorbidity disease in this study was hyperglicemia (20%) and the most common laboratory abnormality was hipoalbuminemia (32%). Systemic corticosteroid was given to 52% patients and the rest (48%) was given combination therapy with immunosuppressant such as mycophenolate mofetil (20%), cyclosporine (16%), and azathioprine (12%). Conclusion: Pemphigus vulgaris mostly affected female between age 51-60 years. Monotherapy with systemic corticosteroid was effective in most patients (52%).